A treatment option that could help

LYNPARZA is a PARP inhibitor. It takes advantage of the fact that BRCA mutations make it hard to repair DNA and uses that deficiency to potentially kill tumor cells in advanced ovarian cancer.

LYNPARZA™ (olaparib) is an oral prescription medicine used to treat women with advanced ovarian cancer who have received previous treatment with 3 or more prior chemotherapy medicines or a combination of chemotherapy medicines for their cancer, and have a certain type of abnormal inherited BRCA gene.

Your healthcare provider will perform a test to make sure that LYNPARZA is right for you.

Introduction to LYNPARZA

BRCA-mutated ovarian cancer is different from other kinds of ovarian cancer.

A BRCA mutation can influence the way cancer responds to different treatments.

In patients with a BRCA mutation, cells have trouble repairing damaged DNA.

LYNPARZA may make it even more difficult for the cells to repair their damaged DNA.

What is the most important information I should know about LYNPARZA?

LYNPARZA may cause serious side effects that can lead to death including:

Bone marrow problems and lung problems. Some people who have ovarian cancer or who have received previous treatment with chemotherapy, radiotherapy or certain other medicines for their cancer have developed bone marrow problems called Myelodysplastic syndrome (MDS) or Acute Myeloid Leukemia (AML) during treatment with LYNPARZA. If you develop MDS or AML, your healthcare provider will stop treatment with LYNPARZA.

Symptoms of low blood cell counts

Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms to discuss with your healthcare provider include:

  • Weakness
  • Weight loss
  • Fever
  • Frequent infections
  • Blood in your urine/stool
  • Shortness of breath
  • Feeling very tired
  • Bruising or bleeding more easily
Blood tests to check blood cell counts

You will undergo blood tests:

  • Before treatment with LYNPARZA to monitor your blood cell counts
  • Every month during treatment with LYNPARZA to monitor your blood cell counts
  • Weekly blood tests will be performed if you have low blood cell counts that last a long time. Your healthcare provider may stop treatment with LYNPARZA until your blood cell counts improve
Lung problems (pneumonitis)

Lung problems (pneumonitis)

Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may do a chest x-ray if you have any of these symptoms. Your healthcare provider may temporarily or completely stop treatment if you develop pneumonitis.

Tell your healthcare provider if you have any of the symptoms above during treatment with LYNPARZA.

DNA damage and repair

DNA is found in all cells of the body.

It is common for one strand or both strands of DNA to break. When that happens, the DNA needs to be repaired.

DNA damage and repair

PARP and BRCA are proteins involved in DNA repair.

PARP and BRCA proteins
PARP Proteins and Repairing DNA

PARP proteins play a key role in repairing DNA when one strand breaks.

BRCA Proteins Repairing DNA

BRCA proteins play a key role in repairing DNA when both strands break.

How LYNPARZA is thought to work

How LYNPARZA™ (olaparib) is thought to work

LYNPARZA is a PARP inhibitor. PARP inhibitors work by inhibiting the activity of PARP proteins, including their role in repairing DNA.

When BRCA proteins are not functioning properly, they are unable to effectively repair DNA.

By introducing a PARP inhibitor, DNA repair may be further prevented, resulting in a buildup of damaged DNA.

The way that LYNPARZA is thought to work makes it a treatment option for women with advanced ovarian cancer who:

  • have a certain type of abnormal inherited BRCA gene, and
  • have received previous treatment with 3 or more prior chemotherapy medicines or a combination of chemotherapy medicines

Your healthcare provider will perform a test to make sure that LYNPARZA is right for you.

It is not known if LYNPARZA is safe and effective in children.

BRCA Testing

See why testing for a BRCA1/BRCA2 mutation is important

Learn more

Am I Eligible for LYNPARZA?

A few quick questions can help determine your eligibility for treatment

Learn more

INDICATION

LYNPARZA is a prescription medicine used to treat women with advanced ovarian cancer who have received previous treatment with 3 or more prior chemotherapy medicines or a combination of chemotherapy medicines for their cancer, and have a certain type of abnormal inherited BRCA gene.

Your healthcare provider will perform a test to make sure that LYNPARZA is right for you.

Please see Important Safety Information below.

IMPORTANT SAFETY INFORMATION

There are no contraindications (a condition in which the treatment should not be used) for LYNPARZA.

LYNPARZA may cause serious side effects that can lead to death including bone marrow problems and lung problems. Some people who have..Read More ovarian cancer or who have received previous treatment with chemotherapy, radiotherapy or certain other medicines for their cancer have developed bone marrow problems called Myelodysplastic syndrome (MDS) or Acute Myeloid Leukemia (AML) during treatment with LYNPARZA. If you develop MDS or AML, your healthcare provider will stop treatment with LYNPARZA.

Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms to discuss with your healthcare provider include weakness, weight loss, fever, frequent infections, blood in your urine/stool, shortness of breath, feeling very tired, and bruising or bleeding more easily.

You will undergo blood tests before, and every month during, treatment with LYNPARZA to monitor your blood cell counts. Weekly blood tests will be performed if you have low blood cell counts that last a long time. Your healthcare provider may stop treatment with LYNPARZA until your blood cell counts improve.

Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may do a chest x-ray if you have any of these symptoms. Your healthcare provider may temporarily or completely stop treatment if you develop pneumonitis (inflammation of the lungs).

Before you take LYNPARZA, tell your healthcare provider about all of your medical conditions including:

  • lung or breathing problems
  • liver problems
  • kidney problems
  • are pregnant or plan to become pregnant. LYNPARZA can harm your unborn baby and may cause loss of pregnancy (miscarriage).
    • If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with LYNPARZA.
    • Females who are able to become pregnant should use effective birth control (contraception) during treatment with LYNPARZA and for 6 months after receiving the last dose of LYNPARZA.
    • Talk to your healthcare provider about birth control methods that may be right for you.
    • Tell your healthcare provider right away if you become pregnant.
  • are breastfeeding or plan to breastfeed. It is not known if LYNPARZA passes into your breast milk. Do not breastfeed during treatment and for 1 month after receiving the last dose of LYNPARZA. Talk to your healthcare provider about the best way to feed your baby.

Avoid grapefruit, grapefruit juice and Seville oranges during treatment as they may increase the levels of LYNPARZA in your blood.

The most common side effects are anemia, nausea or vomiting, tiredness or weakness, diarrhea, indigestion or heartburn, headache, loss of appetite, changes in how food tastes, changes in kidney function blood tests, sore throat or runny nose, upper respiratory infection, cough, pain in the joints, muscles, and back, rash, and pain or discomfort in the stomach area.

These are not all the possible side effects of LYNPARZA. For more information, ask your healthcare provider or pharmacist.

Call your healthcare provider for medical advice about side effects.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088 1-800-FDA-1088.

Please see complete Prescribing Information, including Patient Information (Medication Guide).

The information on this Web site should not take the place of talking with your doctor or healthcare professional. If you have any questions about your condition, or if you would like more information about LYNPARZA, talk to your doctor or pharmacist. Only you and your healthcare professional can decide if LYNPARZA is right for you.